BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32799569)

  • 1. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma.
    Rogers JE; Jácome AAA; Ohinata A; Wolff R; Morris VK; Johnson B; Mehdizadeh A; Rothschild ND; Ahmed SU; Guerra JL; Eng C
    Expert Rev Anticancer Ther; 2020 Oct; 20(10):901-908. PubMed ID: 32799569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor inhibition in metastatic anal cancer.
    Rogers JE; Ohinata A; Silva NN; Mehdizadeh A; Eng C
    Anticancer Drugs; 2016 Sep; 27(8):804-8. PubMed ID: 27272412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA
    Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal.
    Morris V; Rao X; Pickering C; Foo WC; Rashid A; Eterovic K; Kim T; Chen K; Wang J; Shaw K; Eng C
    Mol Cancer Res; 2017 Nov; 15(11):1542-1550. PubMed ID: 28784613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
    Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
    BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
    Kim S; Jary M; André T; Vendrely V; Buecher B; François E; Bidard FC; Dumont S; Samalin E; Peiffert D; Pernot S; Baba-Hamed N; El Hajbi F; Bouché O; Desrame J; Parzy A; Zoubir M; Louvet C; Bachet JB; Nguyen T; Abdelghani MB; Smith D; De La Fouchardière C; Aparicio T; Bennouna J; Gornet JM; Jacquin M; Bonnetain F; Borg C
    BMC Cancer; 2017 Aug; 17(1):574. PubMed ID: 28841909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma.
    De Dosso S; Martin V; Zanellato E; Frattini M; Saletti P
    Tumori; 2010; 96(4):627-8. PubMed ID: 20968146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.
    Siano M; Infante G; Resteghini C; Cau MC; Alfieri S; Bergamini C; Granata R; Miceli R; Locati L; Licitra L; Bossi P
    Oral Oncol; 2017 Jun; 69():33-37. PubMed ID: 28559018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
    Kim DW; Byer J; Kothari N; Mahipal A; Chang YD; Kim RD
    Oncology; 2017; 92(4):190-196. PubMed ID: 28152526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study.
    Morris VK; Salem ME; Nimeiri H; Iqbal S; Singh P; Ciombor K; Polite B; Deming D; Chan E; Wade JL; Xiao L; Bekaii-Saab T; Vence L; Blando J; Mahvash A; Foo WC; Ohaji C; Pasia M; Bland G; Ohinata A; Rogers J; Mehdizadeh A; Banks K; Lanman R; Wolff RA; Streicher H; Allison J; Sharma P; Eng C
    Lancet Oncol; 2017 Apr; 18(4):446-453. PubMed ID: 28223062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
    Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFCIS Treatment and Genomic Correlates of Response in Advanced Anal Squamous Cell Cancer.
    Mondaca S; Chatila WK; Bates D; Hechtman JF; Cercek A; Segal NH; Stadler ZK; Varghese AM; Kundra R; Capanu M; Shia J; Schultz N; Saltz L; Yaeger R
    Clin Colorectal Cancer; 2019 Mar; 18(1):e39-e52. PubMed ID: 30316684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonplatinum-based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population-based Danish anal cancer group study.
    Truelsen CG; Serup-Hansen E; Storm KS; Havelund BM; Kronborg CS; Spindler KG
    Cancer Med; 2021 May; 10(10):3224-3230. PubMed ID: 33960701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
    Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
    Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitomycin and 5-fluorouracil for second-line treatment of metastatic squamous cell carcinomas of the anal canal.
    Saint A; Evesque L; Falk AT; Cavaglione G; Montagne L; Benezery K; Francois E
    Cancer Med; 2019 Nov; 8(16):6853-6859. PubMed ID: 31524335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
    Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
    Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
    Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study.
    Lonardi S; Prete AA; Morano F; Messina M; Formica V; Corsi DC; Orciuolo C; Frassineti GL; Zampino MG; Casagrande M; Masi G; Ronzoni M; Scartozzi M; Buonadonna A; Mosconi S; Ratti M; Sartore-Bianchi A; Tamburini E; Prisciandaro M; Bergamo F; Spada M; Corallo S; Vettore V; Loupakis F; Fassan M; Del Bianco P; Zagonel V; Pietrantonio F
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.